Document is current
Any future updates will be listed below
-
Authors
Valencia, Sarah M. https://orcid.org/0000-0002-8878-8407
Rochat, Eric https://orcid.org/0000-0002-5959-6844
Harnois, Melissa J. https://orcid.org/0000-0002-5910-6198
Dennis, Maria
Webster, Helen S.
Hora, Bhavna
Kumar, Amit
Wang, Hsuan-Yuan https://orcid.org/0000-0001-9248-4281
Li, Leike
Freed, Daniel
Zhang, Ningyan https://orcid.org/0000-0002-4348-2180
An, Zhiqiang https://orcid.org/0000-0001-9309-2335
Wang, Dai https://orcid.org/0000-0001-5666-8622
Permar, Sallie R.
-
Funding
Funding for this research was provided by:
Merck
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (PO1AI129859)
Welch Foundation (AU-0042-20030616)
- License Information
-
More Information
Article History
Received: 26 May 2023
Accepted: 19 September 2023
First Online: 10 October 2023
Competing interests
: S.R.P consults for Merck, Pfizer, GSK, Moderna, Hoopika, and Dynavax CMV vaccine programs and led sponsored programs from Merck, Moderna, and Dynavax around CMV vaccine immunity. D.W and D.F are Merck employees. Other authors (S.M.V, L.L, N.Z, Z.A, E.R, M.J.H., M.D., H.S.W, A.K., B.H. and H-Y.W). declare that there are no competing interests.
